What is this study trying to find out about vulnerability in older men with serious diseases?

This study is exploring the causes and impact of generalized vulnerability in older men with serious diseases including cancers and fractures. It aims to understand how these vulnerabilities affect treatment timing, survival, and quality of life. The research is sponsored by Tampere University Hospital and involves careful observation of patient health and screening methods.

Who may be eligible for this clinical trial on vulnerability in serious diseases?

Men aged 60 or older with suspected or diagnosed serious diseases like prostate cancer, lung cancer, brain metastases, pelvic fractures, or those receiving high-dose chemotherapy may be eligible. Participants must have recent imaging and be able to provide written consent. Please review eligibility criteria for more details.

Is there any cost to participate in this clinical trial?

Study-related care, including all study procedures, is provided at no cost. However, personal travel expenses and other costs related to participation may vary and are not guaranteed to be covered.

Actively Recruiting

MALE

ID07740239

Study on Causes and Impact of Vulnerability in Adult Men With Serious Diseases Including Cancer and Fractures

Led by Tampere University Hospital · Updated on 2026-07-31

2050

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

This research aims to explore the clinical significance and causes of generalized vulnerability in older adult men with serious diseases including various cancers and fractures. It seeks to establish how common these causes are among patients with severe non-cancerous diseases, local and advanced cancers, and how these vulnerabilities affect the time to fully palliative care, overall survival, and quality of life. The study also evaluates how well common screening tools used in non-cancer patients detect vulnerability in older adults with cancer. Participants are men diagnosed with conditions such as prostate cancer, lung cancer, brain metastasis, pelvic fracture, chronic subdural hematoma, or those undergoing high-dose chemotherapy and stem cell transplantation. The study is observational and involves tests designed to determine vulnerability. Patients are required to have recent cross-sectional imaging and study procedures within defined timeframes relative to treatment or hospitalization. No experimental treatments are administered. During the study, participants will undergo assessments to detect causes of vulnerability around the time of study procedures. Researchers will monitor survival, timing of palliative care adoption, and patient-reported quality of life. The study will collect clinical data and imaging results. Participation involves observational data collection without additional treatment, with the study continuing until December 2030.

CONDITIONS

Brief Title

A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial

Who Can Participate

MALE

Eligibility Criteria

You may qualify if you...

Suspected or diagnosed serious disease
Male patients aged 60 years or older, except for patients receiving high-dose chemotherapy and stem cell transplantation who must be 18 years or older
Cross-sectional imaging performed within 45 days before consenting or before the next treatment line
For patients with cancer (except prostate cancer treated with hormonal treatment before radiation): study procedures (excluding image analyses) must be done within 1 month before starting a new treatment line
For prostate cancer patients receiving hormonal treatment before radiation: study procedures must be done within 3 months after starting hormonal treatment
For patients with other conditions: study procedures (excluding image analyses) must be done within 4 days after hospitalization start

You will not qualify if you...

Not willing or unable to provide written consent
Patient considered unsuitable for the study by the researcher approaching them

Research Team

Otso Arponen, Adjunct professor, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here